• Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Life can be better
    We are developing drug products isolated from plant extracts
    with history in traditional medicine.
  • Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Improving health
    Improving health and wellbeing of the people
    is our ultimate goal at Mercury Pharmaceuticals.
  • Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    ENTREPRENEURIAL MINDSET
    Hands-on approach to manage projects with proactivity and flexibility.

Welcome to Mercury Pharmaceuticals


We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.

More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.

Mercury Pharmaceuticals
Technology Assessment
Mercury Pharmaceuticals
Systems Research
Mercury Pharmaceuticals
Innovation Assessment
Mercury Pharmaceuticals
Clinical Trials

OUR Science

The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.

Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.

  • NeuroscienceAmong the global leaders in Neuroscience
  • OncologyTreatments for niche cancers.
  • Research & Development Building a sustainable R&D pipeline.
  • Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

PMOS rethink reframes a common hormone disorder as a whole-body disease

18

Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

READ MORE
New biological age tools could reveal health risks before symptoms appear

18

Jun 2026

New biological age tools could reveal health risks before symptoms appear

A JCI review traces biological age measurement from functional tests and blood biomarkers to epigenetic, proteomic, imaging, wearable, and AI-based clocks. It finds that these tools can improve risk prediction beyond chronological age, but standardization, interpretability, and prospective validation are needed before routine clinical use.

READ MORE
Aircraft emissions could double air pollution deaths by 2040

18

Jun 2026

Aircraft emissions could double air pollution deaths by 2040

Scenario-based modeling projects that aviation-related air pollution could drive a major rise in premature deaths by 2040, mainly through PM2.5 and ozone exposure. The study estimates that aircraft emissions caused 33,900 PM2.5-related deaths and 24,600 ozone-related deaths in 2019, with baseline 2040 deaths projected to more than double.

READ MORE

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.